Morphotek®, Inc., a subsidiary of Eisai Inc., announced that it has commenced a multi-center phase II study of farletuzumab in adenocarcinoma of the lung, a type of non-small cell lung cancer (NSCLC)...
The Good, The Bad And The Ugly, The Many Roles Of C-JUN In Cancer
6/29/2011
The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division...
Texas Workforce Commission Grants Additional Funding To Continue And Expand UH Biotech Program
6/29/2011
Frank Thamma was taking classes at the University of Houston when a flyer touting biotechnology as a career prompted him to enroll in an introductory course. "Taking this course quickly piqued my interest and I changed my major to biotechnology right away," Thamma said. "After enrolling in several courses, I realized how essential and fascinating biotechnology is...
Patients Treated With Sunitinib And Sorafenib Respond To Flu Vaccine
6/28/2011
Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research. Keith Flaherty, M.D...
Mammography Screening Significantly Reduces Breast Cancer Death Rates
6/28/2011
Mammography breast cancer screening reduces death rates significantly in the long-term, researchers report in the journal Radiology. A large-scale Swedish trial found that for the benefits to be appreciated, studies need to evaluate screening over the very long term. Professor of cancer screening at Queen Mary, University of London, Stephen W. Duffy, M.Sc...
ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma...
Advances In Delivery Of Therapeutic Genes To Treat Brain Tumors
6/28/2011
Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases...
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announces the submission of a phase III clinical trial application for Livatag® in the treatment of primary liver cancer to the French Drug Agency (Afssaps)...
Pfizer Announces Data Presentations For Investigational Compounds In Its Lung Cancer Portfolio
6/28/2011
Pfizer Inc...
Different Subtypes Of Triple-Negative Breast Cancer Respond To Different Therapies
6/28/2011
Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer, called "triple-negative breast cancer (TNBC)." In the July issue of the Journal of Clinical Investigation, Cancer Center Director Jennifer Pietenpol, Ph.D...